Lara McGrath

机构：AstraZeneca (United States) · ORCID：0000-0001-6190-4802

发表论文 133 篇 · 总被引 621 次 · h-index 12

代表论文

• Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial (2025 · Nature Medicine · 被引 35)
• Abstract 2961: AZD9592, an EGFR/cMET bispecific antibody-drug conjugate (ADC), demonstrates target-dependent efficacy in colorectal cancer (CRC) patient-derived xenograft (PDX) models (2025 · Cancer Research · 被引 3)
• Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ± novel agents in resectable non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2. (2025 · Journal of Clinical Oncology · 被引 1)
• Data from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial (2023 · 被引 1)
• Abstract 2661: AZD5335, a folate receptor alpha-targeted ADC, exerts anti-tumor responses within lung adenocarcinoma (2026 · Cancer Research)
• Figure S1 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors (2025)